A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis

Digestive and Liver Disease

Volumn 47, Issue 11, 2015, Pages 933-937

  Pica, Roberta ^a   Cassieri, Claudio ^b   Cocco, Andrea ^a   Zippi, Maddalena ^a   Marcheggiano, Adriana ^b   De Nitto, Daniela ^a   Avallone, Eleonora Veronica ^b   Crispino, Pietro ^b   Occhigrossi, Giuseppe ^a   Paoluzi, Paolo ^b  

^a SANDRO PERTINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Daily dosage; Maintenance of remission; Mesalazine; Ulcerative colitis

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; TREATMENT DURATION; ULCERATIVE COLITIS; AGED; BIOPSY; COLITIS, ULCERATIVE; COMPARATIVE STUDY; MAINTENANCE CHEMOTHERAPY; MEDICATION COMPLIANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; RECURRENCE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84945494582     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.07.011     Document Type: Article

References (28)

1. Rowe F.A., Walker J.H., Karp L.C., et al. Factors predicting of response to cyclosporine treatment for severe, steroid resistant ulcerative colitis. American Journal of Gastroenterology 2000, 95:2000-2008.
2. Bebb J.R., Scott B.B. Systematic review: how effective are the usual treatments for ulcerative colitis?. Alimentary Pharmacology and Therapeutics 2004, 20:151-159.
3. Hanauer S., Schwartz J., Robinson M., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial Pentasa Study Group. American Journal of Gastroenterology 1993, 88:1188-1197.
4. Sutherland L.R., May G.R., Shaffer E.A. Sulfasalazine revisited. A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine 1993, 118:540-549.
5. Dew M.J., Hughes P., Harries A.D., et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. British Medical Journal (Clinical Research Ed.) 1982, 285:1012.
6. Ardizzone S., Petrillo M., Imbesi V., et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?. Alimentary Pharmacology and Therapeutics 1999, 13:373-379.
7. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis International Study Group. Alimentary Pharmacology and Therapeutics 1989, 3:183-191.
8. Dew M.J., Harries A.D., Evans N., et al. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. British Medical Journal (Clinical Research Ed.) 1983, 287:23-24.
9. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, 10:CD000544.
10. Kamm M.A. Review article: maintenance of remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics 2002, 16:21-24.
11. Riley S.A., Mani V., Goodman M.J., et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988, 94:1383-1389.
12. Hanauer S.B., Sninsky C.A., Robinson M., et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine 1996, 124:204-211.
13. Fockens P., Mulder C.J., Tytgat G.N., et al. Comparison of the efficacy and safety of 1.5 compared with 3.0g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology & Hepatology 1995, 7:1025-1030.
14. Paoluzi O.A., Iacopini F., Pica R., et al. Comparison of two different daily doses (2.4 vs 1.2g) of oral mesalamine in maintenance of remission in ulcerative colitis patients. Alimentary Pharmacology and Therapeutics 2005, 21:1111-1119.
15. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. British Medical Journal 1964, 1:89-92.
16. Truelove S.C., Richards W.R.D. Biopsy studies in ulcerative colitis. British Medical Journal 1956, 1:1315-1318.
17. Allison M.C., Hamilton-Dutoit S.J., Dhillon A.P., et al. The value of rectal biopsy in distinguish self-limited colitis from early inflammatory bowel disease. Quarterly Journal of Medicine 1987, 65:985-995.
18. Surawicz C.M., Belic L. Rectal biopsy help distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984, 86:104-113.
19. Both H., Torp-Pedersen K., Kreiner S., et al. Clinical appearance at diagnosis of ulcerative colitis and Crohn's disease in a regional patient group. Scandinavian Journal of Gastroenterology 1983, 18:987-991.
20. Riley S.A. What dose of 5-aminosalycilic acid (mesalazine) in ulcerative colitis?. Gut 1998, 42:761-763.
21. Gisbert J.P., Gomollón F., Maté J., et al. Role of the 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review. Digestive Diseases and Sciences 2002, 47:471-488.
22. Feagan B.G. Maintenance therapy for inflammatory bowel disease. American Journal of Gastroenterology 2003, 98:S6-S17.
23. D'Albasio G., Pacini F., Camarri E., et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomised double-blind study. American Journal of Gastroenterology 1997, 92:1143-1147.
24. Hanauer S.B., Sandborn W.J., Kornbluth A., et al. Delayed-release oral mesalamine at 4.8g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology 2005, 100:2478-2485.
25. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
26. Hanauer S.B., Regalli G., Verst-Brasch C. Safety of long-term mesalamine therapy in patients with inflammatory bowel disease. American Journal of Gastroenterology 1996, 91:pA343.
27. Hanauer S.B., Verst-Brasch C., Regalli G. Renal safety of long-term mesalamine therapy in inflammatory bowel disease. Gastroenterology 1997, 112:A991.
28. Feagan B.G., Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, 10:CD440005.